FINWIRES · TerminalLIVE
FINWIRES

$APGE

31 stories mentioning APGEUpdated 22d ago

Every FINWIRES story that references APGE, newest first.

Sectors

Sector Update: Healthcare Stocks Flat to Lower Premarket Monday

Healthcare stocks were flat to lower premarket Monday, with the State Street Health Care Select Sector SPDR ETF (XLV) down 0.1% and the iShares Biotechnology ETF (IBB) inactive.AbbVie (ABBV) has agreed to acquire Apogee Therapeutics (APGE) for $135.11 per share in cash for a total equity value of $10.9 billion. Shares of Apogee Therapeutics were up nearly 47% pre-bell, while AbbVie rose 2.3%.Definium Therapeutics (DFTX) shares were up more than 60% after the company said the phase 3 Emerge trial of a single 100-microgram dose of DT120 orally disintegrating tablet in major depressive disorder met the primary endpoint, along with all key secondary efficacy endpoints.MapLight Therapeutics' (MPLT) phase 2 trial of ML-004 in autism spectrum disorder failed to meet its primary endpoint in social communication, the company said. MapLight Therapeutics stock was up 1.6% premarket.

$ABBV$APGE$DFTX$IBB$MPLT$XLV
Research

Canaccord Genuity Downgrades Apogee Therapeutics to Hold From Buy, Adjusts Price Target to $135.11 From $130

Apogee Therapeutics (APGE) has an average rating of buy and mean price target of $119.50, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)

$APGE
Sectors

Sector Update: Healthcare

Healthcare stocks were steady premarket Monday, with the State Street Health Care Select Sector SPDR ETF (XLV) down 0.3% and the iShares Biotechnology ETF (IBB) inactive.AbbVie (ABBV) has agreed to acquire Apogee Therapeutics (APGE) for $135.11 per share in cash for a total equity value of $10.9 billion. Shares of Apogee Therapeutics were up nearly 47% pre-bell, while AbbVie rose 2.4%.

$ABBV$APGE
Commodities

Exchange-Traded Funds, Equity Futures Higher Pre-Bell Amid Continued US-Iran Talks

The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.2%, and the actively traded Invesco QQQ Trust (QQQ) advanced 0.2% in Monday's premarket activity, as traders focused on continuing US-Iran talks for a potentially positive outcome.US stock futures were higher, with S&P 500 Index futures up 0.1%, Dow Jones Industrial Average up 0.01%, and Nasdaq futures gaining 0.3% before the start of regular trading.Federal Reserve Governor Christopher Waller is slated to speak on Monday.In premarket action, bitcoin was up by 0.7%. Among cryptocurrency ETFs, the cryptocurrency fund ProShares Bitcoin Strategy ETF (BITO) was 2.6% higher, Ether ETF (EETH) advanced 2.4%, and Bitcoin & Ether Market Cap Weight ETF (BETH) gained 0.02%.Power Play:Health CareThe State Street Health Care Select Sector SPDR ETF (XLV) retreated by 0.1%, the Vanguard Health Care Index Fund (VHT) was up 0.2%, while the iShares US Healthcare ETF (IYH) advanced by 0.03%. The iShares Biotechnology ETF (IBB) was 0.8% higher.Apogee Therapeutics (APGE) stock rose more than 47% premarket after AbbVie (ABBV) agreed to acquire Apogee for $135.11 per share in cash for a total equity value of $10.9 billion. AbbVie shares were 1.1% higher.Winners and Losers:IndustrialThe State Street Industrial Select Sector SPDR ETF (XLI) advanced 0.2%, while the Vanguard Industrials Index Fund (VIS) retreated 0.7% and the iShares US Industrials ETF (IYJ) was 0.5% lower.SpaceX (SPCX) stock was down by nearly 4% before the opening bell following a 3.6% fall at the prior close. The Financial Times reported Sunday that the company was assigned MSCI's lowest possible ESG rating, triple-C, just ahead of its $75 billion initial public offering earlier this month.ConsumerThe State Street Consumer Staples Select Sector SPDR ETF (XLP) was down 0.7%, the Vanguard Consumer Staples Index Fund ETF Shares (VDC) retreated 0.1%, and the iShares US Consumer Staples ETF (IYK) was inactive. The State Street Consumer Discretionary Select Sector SPDR ETF (XLY) lost 0.4%. The VanEck Retail ETF (RTH) was inactive, while the State Street SPDR S&P Retail ETF (XRT) was flat.Maplebear (CART) shares were down 2% pre-bell after closing Friday with a 4% rise. The company said Monday it launched a short-form vertical video feature that allows users to browse and shop meal and recipe content within retailer storefronts on its platform.FinancialThe State Street Financial Select Sector SPDR ETF (XLF) retreated 0.2%. Direxion Daily Financial Bull 3X Shares (FAS) was up 0.4%, while its bearish counterpart, Direxion Daily Financial Bear 3X Shares (FAZ), was 0.4% lower.Robinhood Markets (HOOD) shares traded down 2% in early hours activity after the company said it plans to offer $2 billion worth of convertible senior notes due 2029 in a private placement.TechnologyThe State Street Technology Select Sector SPDR ETF (XLK) advanced by 0.4%, and the iShares US Technology ETF (IYW) was 0.1% higher, while the iShares Expanded Tech Sector ETF (IGM) was down 1.6%. Among semiconductor ETFs, the State Street SPDR S&P Semiconductor ETF (XSD) was up 2.2%, while the iShares Semiconductor ETF (SOXX) rose by 1.3%.ServiceNow (NOW) shares were down more than 1% in premarket activity. The company said it has teamed up with Inspira Enterprise to offer the full suite of ServiceNow capabilities to enterprises worldwide through the IT services and consulting firm's platform.EnergyThe iShares US Energy ETF (IYE) was flat, while the State Street Energy Select Sector SPDR ETF (XLE) was up by 0.1%.CMB.TECH (CMBT) stock was up more than 2% before market open after the company said it will charter up to 12 shipping vessels capable of being powered by ammonia to Fortescue, an Australian metals and green-energy enterprise.CommoditiesFront-month US West Texas Intermediate crude oil retreated by 0.9% to $75.17 per barrel on the New York Mercantile Exchange. Natural gas gained by 2.2% to $3.31 per 1 million British Thermal Units. The United States Oil Fund (USO) declined by 1.6%, while the United States Natural Gas Fund (UNG) was 2% higher.Gold futures for July were down by 0.5% to $4,223.20 an ounce on the Comex. Silver futures advanced by 0.1% to $66.84 an ounce. SPDR Gold Shares (GLD) declined by 0.2%, and the iShares Silver Trust (SLV) was 1.1% higher.

Dow JonesNasdaq CompositeS&P 500$ABBV$APGE$BETH$BITO$CART$CMBT$EEM$EETH$EXI$FAS$FAZ$GLD$HOOD$IBB$IGM$IGV$IPK$IVV$IWM$IYE$IYH$IYJ$IYK$IYW$NOW$PMR$QQQ$RTH$SLV$SOXX$SPCX$SPY$UNG$USO$VDC$VHT$VIS$XLE$XLF$XLI$XLK$XLP$XLV$XLY$XRT$XSD
Asia Markets

Update: US Equity Futures Slightly Higher Pre-Bell As US-Iran Talks Start in Switzerland

(Updates with economic data, recent oil price movement, world markets' overview and corporate stock movements.)US equity futures were marginally higher pre-bell Monday as traders considered the latest developments in the initial talks between the US and Iran, which target a more permanent peace deal.Dow Jones Industrial Average futures were 0.2% higher, S&P 500 futures were flat, and Nasdaq futures were 0.3% higher.After a memorandum of agreement was signed last week between US and Iran, US Vice President JD Vance and Iran's parliamentary speaker Mohammad Bagher Qalibaf completed the first round of high-level talks in Switzerland aimed at ending the war in the Middle East. Mediators Pakistan and Qatar said there was "encouraging progress" made in the negotiations, with technical discussions continuing this week.However, shipping stalled in the Strait of Hormuz over the weekend after Iran declared the waterway closed once again due to Israeli strikes in Lebanon, CNBC reported, citing data from maritime intelligence firm Windward. President Donald Trump said in a post on Truth Social that Iran should stop its proxies in Lebanon "from causing trouble." Trump added, "If they don't, we'll hit Iran very hard again, just like we did last week, only harder!!!"FedEx (FDX) and Micron Technology (MU), among others, are scheduled to report quarterly financial results this week.Oil prices were lower, with front-month global benchmark North Sea Brent crude down 2.5% at $78.06 per barrel and US West Texas Intermediate crude 1.7% lower at $74.56 per barrel.The economic calendar is vacant on Monday.In other world markets, Japan's Nikkei closed 1.6% higher, Hong Kong's Hang Seng ended 0.7% lower, and China's Shanghai Composite finished 1.8% higher. Meanwhile, the UK's FTSE 100 was up 0.5%, and Germany's DAX index was flat in Europe's early afternoon session.In equities, Alphabet (GOOG, GOOGL) shares were down 2.1% after Google DeepMind data scientist and Nobel Prize winner John Jumper said he is leaving the company to join Anthropic. SpaceX (SPCX) stock was down 3.8% after a Financial Times report that the company was assigned MSCI's lowest possible ESG rating, triple-C, ahead of its $75 billion initial public offering earlier this month. Robinhood Markets (HOOD) stocks fell 1.3% after the company said it plans to offer $2 billion worth of convertible senior notes due 2029 in a private placement.On the winning side, AbbVie (ABBV) and Apogee Therapeutics (APGE) shares were up 1.1% and 47%, respectively, after the two companies said AbbVie has agreed to acquire Apogee Therapeutics for $135.11 per share in cash for a total equity value of $10.9 billion.

Dow JonesNasdaq CompositeS&P 500$ABBV$APGE$FDX$GOOG$GOOGL$HOOD$MU$SPCX
Wire

Apogee Shares Close to Reflect Atopic Dermatitis Prospects, RBC Says

Apogee Therapeutics (APGE) shares are close to "appropriately" reflecting their prospects in atopic dermatitis following its recent Part B results of zumilokibart, RBC said in a note Monday.RBC conducted a survey to gauge dermatologists' reactions to the data and how they might incorporate zumilokibart into their future clinical practice, the report said.The survey revealed slightly higher-than-expected potential switch expectations but lower-than-expected use in biologics-naives, the note said.The results improve confidence in RBC's $2.5 billion out-year US atopic dermatitis estimates, but not quite enough to warrant increasing its sales estimates, the report said."We are increasing our PoS to better reflect further de-risking both on the clinical and the market side, but we still believe shares are close to appropriately reflecting these prospects," the note said.RBC raised its price target to $97 from $82 while keeping its sector perform rating.Price: $84.66, Change: $-2.27, Percent Change: -2.61%

$APGE
Wire

Apogee Therapeutics, Blackstone Life Sciences Enter Financing Collaboration of Up to $1.3 Billion

Apogee Therapeutics (APGE) entered a strategic financing collaboration with Blackstone (BX) Life Sciences for up to $1.3 billion in non-dilutive capital to support Phase 3 development and potential commercialization of zumilokibart, the company said Wednesday.The financing consists of up to $800 million in synthetic royalty funding and up to $500 million in senior corporate debt available at the mutual consent of Apogee and Blackstone.Under the agreement, Blackstone will provide royalty financing in exchange for low- to mid-single-digit tiered royalties on global sales of zumilokibart over 15 years, with the first $400 million in preapproval funding paid in staged tranches, including $100 million at signing, $100 million upon completion of Phase 3 enrollment and $200 million upon positive Phase 3 data.Apogee said the deal, along with its $1.3 billion cash balance, is expected to fund the company through commercialization without additional equity financing.Shares of Apogee Therapeutics were down more than 17% in Wednesday premarket trading.

$APGE$BX
Insider Trading

Apogee Therapeutics Insider Sold Shares Worth $1,641,711, According to a Recent SEC Filing

Michael Thomas Henderson, Director, Chief Executive Officer, on May 13, 2026, sold 20,000 shares in Apogee Therapeutics (APGE) for $1,641,711. Following the Form 4 filing with the SEC, Henderson has control over a total of 1,115,987 common shares of the company, with 1,115,987 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1974640/000110465926062867/xslF345X05/tm2614621-1_4seq1.xml

$APGE
Insider Trading

Apogee Therapeutics Insider Sold Shares Worth $462,784, According to a Recent SEC Filing

Carl Dambkowski, Chief Medical Officer, on May 06, 2026, sold 5,500 shares in Apogee Therapeutics (APGE) for $462,784. Following the Form 4 filing with the SEC, Dambkowski has control over a total of 207,023 common shares of the company, with 207,023 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1974640/000110465926058129/xslF345X05/tm2613976-1_4seq1.xml

$APGE
Research

Rothschild & Co Redburn Initiates Apogee Therapeutics at Buy

Apogee Therapeutics (APGE) has an average rating of buy and mean price target of $118.31, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)

$APGE
Insider Trading

Apogee Therapeutics Insider Sold Shares Worth $1,651,664, According to a Recent SEC Filing

Michael Thomas Henderson, Director, Chief Executive Officer, on April 08, 2026, sold 20,000 shares in Apogee Therapeutics (APGE) for $1,651,664. Following the Form 4 filing with the SEC, Henderson has control over a total of 1,132,987 common shares of the company, with 1,132,987 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1974640/000110465926042155/xslF345X05/tm2611503-1_4seq1.xml

$APGE

Showing 21-31 of 31

Track with the FINWIRES app suite